Beryl Drugs Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹21.71
- Today's High:
- ₹21.72
- Open Price:
- ₹21.71
- 52W Low:
- ₹8
- 52W High:
- ₹24.7
- Prev. Close:
- ₹22.15
- Volume:
- 8827
Company Statistics
- Market Cap.:
- ₹30.58 million
- Book Value:
- 15.058
- Revenue TTM:
- ₹112.81 million
- Operating Margin TTM:
- -0.36%
- Gross Profit TTM:
- ₹62.07 million
- Profit Margin:
- -4.35%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
Beryl Drugs Limited had its IPO on under the ticker symbol 524606.
The company operates in the Healthcare sector and Drugs - Generic industry. Beryl Drugs Limited has a staff strength of 0 employees.
Stock update
Shares of Beryl Drugs Limited opened at ₹21.71 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹21.71 - ₹21.72, and closed at ₹21.72.
This is a -1.94% slip from the previous day's closing price.
A total volume of 8,827 shares were traded at the close of the day’s session.
In the last one week, shares of Beryl Drugs Limited have slipped by -8.32%.
Beryl Drugs Limited's Key Ratios
Beryl Drugs Limited has a market cap of ₹30.58 million, indicating a price to book ratio of 0.3819 and a price to sales ratio of 0.263.
In the last 12-months Beryl Drugs Limited’s revenue was ₹112.81 million with a gross profit of ₹62.07 million and an EBITDA of ₹7.03 million. The EBITDA ratio measures Beryl Drugs Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Beryl Drugs Limited’s operating margin was -0.36% while its return on assets stood at 0% with a return of equity of 0%.
In Q2, Beryl Drugs Limited’s quarterly earnings growth was a positive 0% while revenue growth was a negative 36.3%.
Beryl Drugs Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 4.5833
- PEG
Its diluted EPS in the last 12-months stands at ₹-0.923 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Beryl Drugs Limited’s profitability.
Beryl Drugs Limited stock is trading at a EV to sales ratio of 0.5395 and a EV to EBITDA ratio of 4.1309. Its price to sales ratio in the trailing 12-months stood at 0.263.
Beryl Drugs Limited stock pays annual dividends of ₹ per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹0
- Total Liabilities
- ₹0
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Beryl Drugs Limited ended 2024 with ₹0 in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹0 while shareholder equity stood at ₹0.
Beryl Drugs Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹0 in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.
Beryl Drugs Limited’s total current assets stands at ₹0 while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹0 compared to accounts payable of ₹0 and inventory worth ₹0.
In 2024, Beryl Drugs Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Beryl Drugs Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹21.72
- 52-Week High
- ₹24.7
- 52-Week Low
- ₹8
- Analyst Target Price
- ₹
Beryl Drugs Limited stock is currently trading at ₹21.72 per share. It touched a 52-week high of ₹24.7 and a 52-week low of ₹24.7. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹18.73 and 200-day moving average was ₹14.84 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 3329.4% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Beryl Drugs Limited
Similar Industry Stocks (Drugs - Generic)
Most Active
Top Gainers
Top Losers
About
Beryl Drugs Limited manufactures and markets branded and generic pharmaceutical formulations in India. The company offers I.V. fluids and small volume injectables, as well as veterinary products. It also provides research and development, and contract manufacturing services. Beryl Drugs Limited was founded in 1993 and is based in Indore, India.